A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
(DUET-4 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called XmAb22841 alone and with another drug, pembrolizumab, in patients with advanced solid tumors. The goal is to find the safest dose and see how well these drugs work together. Both drugs aim to boost the immune system to better fight cancer. Pembrolizumab has been shown to be an effective and safe therapeutic option in various cancers, including melanoma, prostate cancer, and endometrial cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that certain treatments, like systemic antineoplastic therapy and some antibodies, should not be taken close to the start of the study. It's best to discuss your specific medications with the trial team.
What safety data exists for Pembrolizumab (Keytruda) in humans?
Pembrolizumab (Keytruda) has been associated with some immune-related side effects, including a rare risk of developing type 1 diabetes in 0.2% of cases. Common side effects include fatigue, cough, nausea, itching, rash, decreased appetite, constipation, joint pain, and diarrhea. Serious immune-related side effects can include lung inflammation, liver inflammation, and thyroid disorders.12345
What data supports the effectiveness of the drug Pembrolizumab (Keytruda) in treating cancer?
Who Is on the Research Team?
Benjamin Thompson, MD, PhD
Principal Investigator
Xencor, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive XmAb®22841 monotherapy or in combination with pembrolizumab in a multiple dose, ascending-dose escalation study
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pembrolizumab
- XmAb®22841
Pembrolizumab is already approved in United States, European Union, United Kingdom for the following indications:
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xencor, Inc.
Lead Sponsor
ICON Clinical Research
Industry Sponsor